首页> 外文期刊>Practical Laboratory Medicine >Enzymatic measurement of ether phospholipids in human plasma after hydrolysis of plasma with phospholipase A 1
【24h】

Enzymatic measurement of ether phospholipids in human plasma after hydrolysis of plasma with phospholipase A 1

机译:用磷脂酶A 1 水解血浆后,酶法测定人血浆中的醚磷脂

获取原文
       

摘要

Objectives Ethanolamine ether phospholipids (ePE) and choline ether phospholipid (ePC) are present in human serum or plasma. Decreases in ether phospholipids (plasmalogens) in serum (plasma) have been reported in several diseases such as Alzheimer's disease, Parkinson's disease, metabolic syndrome, schizophrenia. Therefore, need for assay of ether phospholipids in plasma may increase in the future. Nowadays, measurement of the ether phospholipids in human plasma seem to depend on tandem mass spectrometry (LC/MS/MS), but a system for LC/MS/MS is too expensive for most of ordinary clinical laboratories, moreover, use and maintenance of the system are time consuming. Design and methods Phospholipase A 1 (PLA1) hydrolyzes ester (acyl) bond at the sn-1 position of glycerophospholipids, but it does not act on ether bond at the sn-1 position. We confirmed by a HPLC method that treatment of plasma with PLA1 causes complete disappearance of all diacyl phospholipids, but ether phospholipids remain intact. On the basis of these observations, we developed an enzymatic assay method for ePE and ePC in human plasma by use of a fluorescence plate reader. Results The amount of ePE in human plasma measured by the enzymatic method was well correlated to that by LC/ESI-MS method (R 2 > 0.94), but the correlation of ePC between the two methods was bit poorer (R 2 > 0.77) than that of ePE. Conclusion The enzymatic method may be applied to assay of ether phospholipids (ePE and ePC) not only in human plasma but also to assay of ePE and ePC in the other tissues. Highlights ? Enzymatic assay method of ether phospholipids in human plasma. ? To our knowledge, the first report of enzymatic assay method of ether phospholipids. ? The enzymatic method correlate with HPLC-ELSD method. ? The method may be applicable to many tissues other than human plasma.
机译:目的乙醇胺醚磷脂(ePE)和胆碱醚磷脂(ePC)存在于人血清或血浆中。血清(血浆)中的醚磷脂(血浆原)的减少已报道在几种疾病中,例如阿尔茨海默氏病,帕金森氏病,代谢综合征,精神分裂症。因此,将来可能需要增加血浆中醚磷脂的含量。如今,人血浆中醚磷脂的测定似乎依赖于串联质谱(LC / MS / MS),但是LC / MS / MS的系统对于大多数普通临床实验室来说太昂贵了,此外,它的使用和维护该系统非常耗时。设计和方法磷脂酶A 1(PLA1)水解甘油磷脂的sn-1位置的酯(酰基)键,但不作用于sn-1位置的醚键。我们通过HPLC方法证实,用PLA1处理血浆会导致所有二酰基磷脂完全消失,但醚磷脂保持完整。基于这些观察结果,我们通过使用荧光板读数器开发了用于人血浆中ePE和ePC的酶法测定方法。结果酶法测定人血浆中ePE的含量与LC / ESI-MS法相关(R 2> 0.94),但两种方法中ePC的相关性较差(R 2> 0.77)比ePE结论酶法不仅可以用于人体血浆中醚磷脂(ePE和ePC)的测定,还可以用于其他组织中ePE和ePC的测定。强调 ?人血浆中醚磷脂的酶法测定。 ?据我们所知,第一个酶法测定醚磷脂的报道。 ?酶法与HPLC-ELSD法相关。 ?该方法可以适用于人类血浆以外的许多组织。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号